Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 7, 2013, Pages 2885-2903

  Ye, Na ^a   Chen, Chuan Huizi ^a   Chen, Tiantian ^a   Song, Zilan ^a   He, Jin Xue ^a   Huan, Xia Juan ^a   Song, Shan Shan ^a   Liu, Qiufeng ^a   Chen, Yi ^a   Ding, Jian ^a   Xu, Yechun ^a   Miao, Ze Hong ^a   Zhang, Ao ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [2 FLUORO 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZOYL]PIPERIDINE 4 CARBONYL] 2,3,9,9A TETRAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE; 1 [1 [2 FLUORO 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZOYL]PYRROLIDINE 2 CARBONYL] 2,3,9,9A TETRAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE; 1 [2 FLUORO 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZOYL] 2,3,8,8A TETRAHYDROCYCLOPENTA[IJ]ISOQUINOLIN 7(1H)ONE; 1 [2 FLUORO 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZOYL] 2,3,9,9A TETRAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE; 1 [2 FLUORO 5 [(4 OXO 3,4,5,6,7,8 HEXAHYDROPHTHALAZIN 1 YL)METHYL]BENZOYL] 2,3,9,9A TETRAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE; 1 [2 FLUORO 5 [(5 METHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL)METHYL]BENZOYL] 2,3,9,9A TETRAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE; 1 [5 [(4,5 DIMETHYL 6 OXO 1,6 DIHYDROPYRIDAZIN 3 YL)METHYL] 2 FLUOROBENZOYL] 2,3,9,9A TETRAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE; 2 FLUORO N (1 OXO 1,2,3,4 TETRAHYDROISOQUINOLIN 4 YL) 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZAMIDE; 2 FLUORO N (3 OXO 2,3 DIHYDRO 1H INDEN 1 YL) 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZAMIDE; 2 FLUORO N (ANTI 3 HYDROXY 2,3 DIHYDRO 1H INDEN 1 YL) 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZAMIDE; 2 FLUORO N (SYN 3 HYDROXY 2,3 DIHYDRO 1H INDEN 1 YL) 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZAMIDE; 2 FLUORO N [2 OXO 2 (7 OXO 2,3,7,8,9,9A HEXAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDIN 1 YL)ETHYL] 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZAMIDE; 4 [2 FLUORO 5 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZOYL] 3A,4,5,6 TETRAHYDRO 1H BENZO[DE][1,6]NAPHTHYRIDIN 2(3H)ONE; 4 [3 (7 AMINO 1,2,3,7,8,8A HEXAHYDROCYCLOPENTA[IJ]ISOQUINOLINE 1 CARBONYL) 4 FLUOROBENZYL]PHTHALAZIN 1(2H)ONE; 4 [4 FLUORO 3 (2,3,7,8,9,9A HEXAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDINE 1 CARBONYL)BENZYL]PHTHALAZIN 1(2H)ONE; 4 [4 FLUORO 3 (2,3,7,8,9,9A HEXAHYDRO 1H BENZO[DE][1,7]NAPHTHYRIDINE 8 CARBONYL)BENZYL]PHTHALAZIN 1(2H)ONE; 4 [4 FLUORO 3 (7 FLUORO 1,2,3,7,8,8A HEXAHYDROCYCLOPENTA[IJ]ISOQUINOLINE 1 CARBONYL)BENZYL]PHTHALAZIN 1(2H)ONE; 4 [4 FLUORO 3 (7 HYDROXY 1,2,3,7,8,8A HEXAHYDROCYCLOPENTA[IJ]ISOQUINOLINE 1 CARBONYL)BENZYL]PHTHALAZIN 1(2H)ONE; APOMORPHINE; BENZO[DE][1,7]NAPHTHYRIDIN 7(8H)ONE DERIVATIVE; HYDROGEN PEROXIDE; INIPARIB; N (1 OXO 1,2,3,4 TETRAHYDROISOQUINOLIN 4 YL) 3 [(4 OXO 3,4 DIHYDROPHTHALAZIN 1 YL)METHYL]BENZAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE ARREST; CELL STRAIN; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DISTRIBUTION VOLUME; DOUBLE STRANDED DNA BREAK; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; IC 50; NONHUMAN; PLASMA CLEARANCE; PROTEIN DOMAIN; RAT;

ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GENES, BRCA1; GENES, BRCA2; INHIBITORY CONCENTRATION 50; NAPHTHYRIDINES; POLY(ADP-RIBOSE) POLYMERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876257495     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301825t     Document Type: Article

References (69)

1. Gibson, B. A.; Kraus, W. L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs Nature Rev. Mol. Cell Biol. 2012, 13, 411-424
2. Burkle, A. Poly(ADP-ribose). The most elaborate metabolite of NAD+ FEBS J. 2005, 272, 4576-4589
3. Krishnakumar, R.; Kraus, W. L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets Mol. Cell 2010, 39, 8-24
4. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule Nature Rev. Mol. Cell Biol. 2006, 7, 517-528
5. Yelamos, J.; Schreiber, V.; Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2 Trends Mol. Med. 2008, 14, 169-178
6. Yelamos, J.; Farres, J.; Llacuna, L.; Ampurdanes, C.; Martin-Caballero, J. PARP-1 and PARP-2: new players in tumour development Am. J. Cancer Res. 2011, 1, 328-346
7. Sandhu, S. K.; Yap, T. A.; de Bono, J. S. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective Eur. J. Cancer. 2010, 46, 9-20
8. Langelier, M. F.; Servent, K. M.; Rogers, E. E.; Pascal, J. M. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation J. Biol. Chem. 2008, 283, 4105-4114
9. 3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction J. Biol. Chem. 2010, 285, 18877-18887
10. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R. A. DNA repair pathways as targets for cancer therapy Nature Rev. Cancer 2008, 8, 193-204
11. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005, 434, 913-917
12. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005, 434, 917-921
13. Peralta-Leal, A.; Rodriguez, M. I.; Oliver, F. J. Poly(ADP-ribose) polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment Clin. Transl. Oncol. 2008, 10, 318-323
14. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond Nature Rev. Cancer 2010, 10, 293-301
15. Ferraris, D. V. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J. Med. Chem. 2010, 53, 4561-4584
16. Amir, E.; Seruga, B.; Serrano, R.; Ocana, A. Targeting DNA repair in breast cancer: a clinical and translational update Cancer Treat. Rev. 2010, 36, 557-565
17. Heitz, F.; Harter, P.; Ewald-Riegler, N.; Papsdorf, M.; Kommoss, S.; du Bois, A. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy Expert. Rev. Anticancer Ther. 2010, 10, 1125-1136
18. Glendenning, J.; Tutt, A. PARP inhibitors-current status and the walk towards early breast cancer Breast 2011, 20 (Suppl 3) S12-S19
19. Wang, Z.; Wang, F.; Tang, T.; Guo, C. The role of PARP1 in the DNA damage response and its application in tumor therapy Front. Med. 2012, 6, 156-164
20. Basu, B.; Yap, T. A.; Molife, L. R.; de Bono, J. S. Targeting the DNA damage response in oncology: past, present and future perspectives Curr. Opin. Oncol. 2012, 24, 316-324
21. De Vos, M.; Schreiber, V.; Dantzer, F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art Biochem. Pharmacol. 2012, 84, 137-146
22. Kummar, S.; Chen, A.; Parchment, R. E.; Kinders, R. J.; Ji, J.; Tomaszewski, J. E.; Doroshow, J. H. Advances in using PARP inhibitors to treat cancer BMC Med. 2012, 10, 25
23. Patel, A.; Kaufmann, S. H. Development of PARP inhibitors: an unfinished story Oncology 2010, 24, 66-68
24. Patel, A. G.; De Lorenzo, S. B.; Flatten, K. S.; Poirier, G. G.; Kaufmann, S. H. Clin. Cancer Res. 2012, 18, 1655-1662
25. Calabrese, C. R.; Almassy, R.; Barton, S.; Batey, M. A.; Calvert, A. H.; Canan-Koch, S.; Durkacz, B. W.; Hostomsky, Z.; Kumpf, R. A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D. R.; Notarianni, E.; Stratford, I. J.; Skalitzky, D.; Thomas, H. D.; Wang, L. Z.; Webber, S. E.; Williams, K. J.; Curtin, N. J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 J. Natl. Cancer Inst. 2004, 96, 56-67
26. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X. L.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr.; Matthews, I. T.; Moore, S.; O'Connor, M. J.; Smith, G. C.; Martin, N. M. 4-[3-(4- Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H -phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1 J. Med. Chem. 2008, 51, 6581-6591
27. Donawho, C. K.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin. Cancer Res. 2007, 13, 2728-2737
28. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 2010, 376, 245-251
29. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 2010, 376, 235-244
30. Yamamoto, N.; Nokihara, H.; Yamada, Y.; Goto, Y.; Tanioka, M.; Shibata, T.; Yamada, K.; Asahina, H.; Kawata, T.; Shi, X.; Tamura, T. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors Cancer Sci. 2012, 103, 504-509
31. Dean, E.; Middleton, M. R.; Pwint, T.; Swaisland, H.; Carmichael, J.; Goodege-Kunwar, P.; Ranson, M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours Br. J. Cancer 2012, 106, 468-474
32. Gelmon, K. A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; Yerushalmi, R.; Macpherson, E.; Carmichael, J.; Oza, A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol. 2011, 12, 852-861
33. AstraZeneca Updates on Olaparib and TC-5214 Development Programmes; http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates- olaparib-TC5214-development; (accessed Dec, 2012).
34. Ellisen, L. W. PARP inhibitors in cancer therapy: promise, progress, and puzzles Cancer Cell 2011, 19, 165-167
35. Khasraw, M.; Robson, M. Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges Clin. Invest. 2011, 1, 1545-1554
36. Penning, T. D. Small-molecule PARP modulators-current status and future therapeutic potential Curr. Opin. Drug Discovery Dev. 2010, 13, 577-586
37. Davar, D.; Beumer, J. H.; Hamieh, L.; Tawbi, H. Role of PARP inhibitors in cancer biology and therapy Curr. Med. Chem. 2012, 19, 3907-3921
38. Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders Chem. Rev. 2007, 107, 274-302
39. 1A dual-agonist profile J. Med. Chem. 2011, 54, 4324-4338
40. 1A receptor agonist J. Med. Chem. 2010, 53, 1319-1328
41. Torrisi, C.; Bisbocci, M.; Ingenito, R.; Ontoria, J. M.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Jones, P. Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1) Bioorg. Med. Chem. Lett. 2010, 20, 448-452
42. Pelletier, J. C.; Cava, M. P. Synthesis of the Marine Alkaloids Aaptamine and Demethyloxyaaptamine and of the Parent Structure Didemethoxyaaptamine J. Org. Chem. 1987, 52, 616-622
43. Pushpan, S.; Ramachandran, U.; Kundu, M.; Anantharaman, V.; Subramanian, S.; Viswanathan, R.; Tadiparthi, R.; Paul-Sathyaseela, M.; Solanki, S. S.; Koppolu, K.; [(Piperazinylphenyl)oxooxazolidinyl]methyl amide derivatives as antibacterial agents and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections. PCT Int. Appl. 2009001192, 2008.
44. Martin, N. M.; Smith, G. C.; Jackson, S. P.; Loh, V. M.; Matthews, I. T. W.; Menear, K. A.; Kerrigan, F.; Ashworth, A. Preparation of phthalazinones as PARP inhibitors. U.S. Patent 20050059663, 2005.
45. Gandhi, V. B.; Giranda, V. L.; Gong, J.-C.; Penning, T. D.; Zhu, G.-D. Inhibitors of Poly(ADP-Ribose) Polymerase. U.S. Patent 20080161280, 2009.
46. Jones, P.; Kinzel, O.; Pescatore, G.; Llauger, B. L.; Schultz-Fademrecht, C.; Ferrigno, F. Preparation of pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp). PCT Int. Appl. 2007138351, 2007.
47. Tangallapally, R. P.; Lee, R. E.; Lenaerts, A. J. Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability Bioorg. Med. Chem. Lett. 2006, 16, 2584-2589
48. Cockcroft, X. L.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; Kerrigan, F.; Loh, V. M., Jr.; Martin, N. M.; Menear, K. A.; Smith, G. C. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose) polymerase Bioorg. Med. Chem. Lett. 2006, 16, 1040-1044
49. Ricci, G.; Ruzziconi, R. Regioselectively nucleus and/or side-chain fluorinated 2-(phenanthryl)propionic acids by an effective combination of radical and organometallic chemistry J. Org. Chem. 2005, 70, 611-623
50. Dong, L.; Aleem, S.; Fink, C. A. Microwave-accelerated reductive amination between ketones and ammonium acetate Tetrahedron Lett. 2010, 51, 5210-5212
51. Gonzalez-Diaz, H.; Prado-Prado, F.; Garcia-Mera, X.; Alonso, N.; Abeijon, P.; Caamano, O.; Yanez, M.; Munteanu, C. R.; Pazos, A.; Dea-Ayuela, M. A.; Gomez-Munoz, M. T.; Garijo, M. M.; Sansano, J.; Ubeira, F. M. MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae J. Proteome Res. 2011, 10, 1698-1718
52. Dallemagne, P.; Tembo, O.; Rault, S.; Robba, M. Synthesis of 4-amino-1-isoquinolinones by rearrangement of 3-amino-1-indanones Bull. Soc. Chim. Fr. 1989, 98-103
53. Weygand, F.; Swodenk, W. N -Trifluoroamino acids. IX. Peptide syntheses with N -trifluoroacetylamino acid cyanomethyl esters Chem. Ber. 1957, 90, 639
54. Wiegant, W. W.; Overmeer, R. M.; Godthelp, B. C.; van Buul, P. P.; Zdzienicka, M. Z. Chinese hamster cell mutant, V-C8, a model for analysis of BRCA2 function Mutat. Res. 2006, 600, 79-88
55. Wang, Y.; Ai, J.; Wang, Y.; Chen, Y.; Wang, L.; Liu, G.; Geng, M.; Zhang, A. Synthesis and c-Met kinase inhibition of 3,5-di- and 3,5,7-tri-substituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)- 7-(trifluoromethyl)quinoline as a novel anticancer agent J. Med. Chem. 2011, 54, 2127-2142
56. Wang, Y.; Ai, J.; Yue, J.; Peng, X.; Ji, Y.; Zhao, A.; Gao, X.; Wang, Y.; Chen, Y.; Liu, G.; Gao, Z.; Geng, M.; Zhang, A. Further SAR Studies on 3,5-Diamino-7-trifluoromethylquinolines as Highly Potent Tyrosine Kinase c-Met Inhibitors: Efforts to Correct hERG Inhibition Med. Chem. Commun. 2012, 3, 1423-1427
57. Fortini, P.; Ferretti, C.; Pascucci, B.; Narciso, L.; Pajalunga, D.; Puggioni, E. M.; Castino, R.; Isidoro, C.; Crescenzi, M.; Dogliotti, E. DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity Cell Death Differ. 2012, 19, 1741-1749
58. Hu, X. Y.; Fang, Q.; Wang, J. S.; Xie, J. Q.; Chai, B. S.; Li, F. Q.; Cui, X.; Yang, Y. Over-expression of aldehyde dehydrogenase-2 protects against H(2)O(2)-induced oxidative damage and apoptosis in peripheral blood mononuclear cells Acta Pharmacol. Sin. 2011, 32, 245-252
59. He, J. X.; Yang, C. H.; Miao, Z. H. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics Acta Pharmacol. Sin. 2010, 31, 1172-1180
60. Bonner, W. M.; Redon, C. E.; Dickey, J. S.; Nakamura, A. J.; Sedelnikova, O. A.; Solier, S.; Pommier, Y. GammaH2AX and cancer Nature Rev. Cancer 2008, 8, 957-967
61. Penning, T. D.; Zhu, G. D.; Gong, J.; Thomas, S.; Gandhi, V. B.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Park, C. H.; Fry, E. H.; Donawho, C. K.; Frost, D. J.; Buchanan, F. G.; Bukofzer, G. T.; Rodriguez, L. E.; Bontcheva-Diaz, V.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Giranda, V. L. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1 H -benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor J. Med. Chem. 2010, 53, 3142-3153
62. Penning, T. D.; Zhu, G. D.; Gandhi, V. B.; Gong, J.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Giranda, V. L. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H -benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer J. Med. Chem. 2009, 52, 514-523
63. Tong, Y.; Bouska, J. J.; Ellis, P. A.; Johnson, E. F.; Leverson, J.; Liu, X.; Marcotte, P. A.; Olson, A. M.; Osterling, D. J.; Przytulinska, M.; Rodriguez, L. E.; Shi, Y.; Soni, N.; Stavropoulos, J.; Thomas, S.; Donawho, C. K.; Frost, D. J.; Luo, Y.; Giranda, V. L.; Penning, T. D. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents J. Med. Chem. 2009, 52, 6803-6813
64. Jones, P.; Altamura, S.; Boueres, J.; Ferrigno, F.; Fonsi, M.; Giomini, C.; Lamartina, S.; Monteagudo, E.; Ontoria, J. M.; Orsale, M. V.; Palumbi, M. C.; Pesci, S.; Roscilli, G.; Scarpelli, R.; Schultz-Fademrecht, C.; Toniatti, C.; Rowley, M. Discovery of 2-{4-[(3 S)-piperidin-3-yl]phenyl}-2 H -indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors J. Med. Chem. 2009, 52, 7170-7185
65. Zhu, G. D.; Gong, J.; Gandhi, V. B.; Liu, X.; Shi, Y.; Johnson, E. F.; Donawho, C. K.; Ellis, P. A.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Park, C.; Luo, Y.; Shoemaker, A.; Giranda, V. L.; Penning, T. D. Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer Bioorg. Med. Chem. 2012, 20, 4635-4645
66. Ferrigno, F.; Branca, D.; Kinzel, O.; Lillini, S.; Llauger Bufi, L.; Monteagudo, E.; Muraglia, E.; Rowley, M.; Schultz-Fademrecht, C.; Toniatti, C.; Torrisi, C.; Jones, P. Development of substituted 6-[4-fluoro-3-(piperazin-1- ylcarbonyl)benzyl]-4,5 -dimethylpyridazin-3(2 H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells Bioorg. Med. Chem. Lett. 2010, 20, 1100-1105
67. Kinoshita, T.; Nakanishi, I.; Warizaya, M.; Iwashita, A.; Kido, Y.; Hattori, K.; Fujii, T. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase FEBS Lett. 2004, 556, 43-46
68. Hattori, K.; Kido, Y.; Yamamoto, H.; Ishida, J.; Kamijo, K.; Murano, K.; Ohkubo, M.; Kinoshita, T.; Iwashita, A.; Mihara, K.; Yamazaki, S.; Matsuoka, N.; Teramura, Y.; Miyake, H. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase J. Med. Chem. 2004, 47, 4151-4154
69. Manzo, S. G.; Zhou, Z. L.; Wang, Y. Q.; Marinello, J.; He, J. X.; Li, Y. C.; Ding, J.; Capranico, G.; Miao, Z. H. Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II Cancer Res. 2012, 72, 5363-5373